Retrospective Study
Copyright ©The Author(s) 2021.
World J Hepatol. Jan 27, 2022; 14(1): 244-259
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.244
Table 1 Computed tomography acquisition parameters in study cohort
CT scanner model
Number of study cases (n)
Detector collimation
Spiral pitch factor
Rotation time (s)
Voltage (kVp)
Tube current-time product at level of liver metastases (mAs)
Noise Index
Reconstruction kernel
Slice thickness/reconstruction interval (mm)
Field of view (cm)
Matrix size (pixels)
GE Lightspeed RT161616 × 1.25 mm1.375:10.8 (n = 14); 0.9 (n = 1); 1.0 (n = 1)120 (n = 14); 140 (n = 2)96-30011.5SOFT1.25/1.2550512 × 512
GE Optima CT5401116 × 1.25 mm1.375:1 (n = 9); 0.938:1 (n = 2)0.7 (n = 6); 0.8 (n = 4); 0.9 (n = 1)120109.6-277.211.5 -13SOFT1.25/1.2550512 × 512
GE Discovery IQ216 × 1.25 mm0.938:10.8120155.2 and 209.611-11.5SOFT1.25/1.2550512 × 512
Table 2 Characteristics of the patients, overall and by response to first-line chemotherapy
All
Responders
Non-responders
P valuea

n
%
n
%
n
%

Age at diagnosis (yr)159(52-73)60(52-74)59(54-71)0.79
Sex1.00
Female11(38)6(40)5(36)
Male18(62)9(60)9(64)
Position of colorectal Tumor 0.71
Colon (incl. rectosigmoid)18(62)10(67)8(57)
Rectum11(38)5(33)6(43)
T-stage of the primary tumor1.00
T322(81)11(85)11(79)
T45(19)2(15)3(21)
Unknown220
N-stage of the primary tumor0.85
N05(22)2(20)3(23)
N15(22)3(30)2(15)
N213(57)5(50)8(62)
Unknown651
Primary CRC grade0.60
Moderate25(86)12(80)13(93)
Poor4(14)3(20)1(7)
M-stage of the primary tumor1.00
M03(10)2(13)1(7)
M126(90)13(87)13(93)
KRAS mutation status1.00
Wild type5(42)2(40)3(43)
Mutant7(58)3(60)4(57)
Unknown17107
Extent of metastatic disease0.71
Liver only18(62)10(67)8(57)
Liver and extrahepatic11(38)5(33)6(43)
CRLM timing
Synchronous26(90)13(87)13(93)1.00
Metachronous3(10)2(13)1(7)
Number of metastases0.05
≤ 510(34)2(13)8(57)
6-107(24)5(33)2(14)
> 1012(41)8(53)4(29)
Maximum size of metastases (mm)0.49
< 308(28)4(27)4(29)
30-7015(52)9(60)6(43)
> 706(21)2(13)4(29)
Target liver metastases
Baseline maximum transverse diameter (cm)12.7(2.0-3.3)2.9(2.6-3.4)2.4(1.8-3.0)0.14
Baseline lesion volume (cm³)17.7(3.6-12.7)8.3(6.2-12.2)5.2(3.1-12.3)0.32
CEA (ng/mL)1107(10-171)130(28-239)51(11-136)0.24
CA19-9 (IU/mL)1,2127(37-377)136(40-327)59(21-773)0.77
Table 3 Summary of Response Evaluation Criteria in Solid Tumors response and chemotherapy regimes in response and non-response group

Response group
Non-response group
RECIST response
CR0
PR15
SD7
PD7
Chemotherapy regimen
FOLFOX44
FOLFIRI43
FOLFOXIRI20
CAPE-OX23
CAPE-IRI23
Capecitabine11
Number of chemotherapy cycles between baseline and follow-up scan
Range in cycles (median)3-12 (8)3-12 (6)
Time between baseline and follow-up scan
Range in d (median)72-203 (141)76-198(111)
Table 4 Radiomic features associated with response to chemotherapy
Univariable models
Multiple model

OR (95%CI)
P value1
AUC
OR (95%CI)
P value1
AUC
Minimum histogram gradient intensity3.82 (1.26-15.3)0.020.743.24 (1.05-12.00)0.040.80
Discretized intensity skewness0.33 (0.11-0.86)0.020.73
Skewness0.33 (0.11-0.86)0.020.73
Long run low grey level emphasis3.01 (1.16-9.26)0.020.732.84 (0.98-10.09)0.05
Low grey level count emphasis3.01 (1.16-9.26)0.020.73
Low grey level run emphasis3.01 (1.16-9.26)0.020.73
Volume at intensity fraction 10%0.33 (0.11-0.86)0.020.73
Short run low grey level emphasis2.83 (1.08-8.81)0.030.71